ProCE Banner Activity

Targeting CD123 in AML

Clinical Thought
Targeting CD123 in AML with multiple approaches shows promise as a novel treatment for this challenging disease.

Released: June 28, 2016

Expiration: June 27, 2017

No longer available for credit.

Share

Faculty

Jonathan Webster

Jonathan Webster, MD

Fellow
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Baltimore, Maryland

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational donation from

Amgen, Inc.

Faculty Disclosure

Primary Author

Jonathan Webster, MD

Fellow
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Baltimore, Maryland

Jonathan Webster, MD, has no real or apparent conflicts of interest to report.